Back to Search Start Over

Determination of copper and other trace elements in serum samples from patients with biliary tract cancers: prospective noninterventional nonrandomized clinical study protocol.

Authors :
Rebersek M
Hribernik N
Markovic K
Markovic S
Valentinuzzi KU
Cemazar M
Zuliani T
Milacic R
Scancar J
Source :
Radiology and oncology [Radiol Oncol] 2024 Mar 30; Vol. 58 (2), pp. 300-310. Date of Electronic Publication: 2024 Mar 30 (Print Publication: 2024).
Publication Year :
2024

Abstract

Background: Biliary tract cancers (BTCs) are usually diagnosed at an advanced stage, when the disease is incurable. Currently used tumor biomarkers have limited diagnostic value for BTCs, so there is an urgent need for sensitive and specific biomarkers for their earlier diagnosis. Deregulation of the homeostasis of trace elements is involved in the carcinogenesis of different cancers, including BTCs. The objective of the study is to determine/compare the total concentrations of copper (Cu), zinc (Zn) and iron (Fe) and the proportions of free Cu and Cu bound to ceruloplasmin (Cp) and the isotopic ratio of <superscript>65</superscript> Cu/ <superscript>63</superscript> Cu in serum samples from healthy volunteers and cancer patients using inductively coupled plasma-mass spectrometry-based methods (ICP-MS).<br />Patients and Methods: In this prospective, noninterventional, nonrandomized study 20 patients and 20 healthy volunteers will be enrolled to identify serum Cu, Zn and Fe levels, Cu isotopic fractionation as a predictive biomarker of response to systemic therapy of BTCs, which will be evaluated by computed tomography. Newly developed analytical methods based on ICP-MS will be applied to metal-based biomarker research in oncology.<br />Conclusions: In the study the comparison of the total concentration of selected trace elements, the proportion of free Cu and Cu bound to Cp and the isotopic ratio of <superscript>65</superscript> Cu/ <superscript>63</superscript> Cu in serum samples from healthy volunteers and cancer patients will be conducted to provide the foundation for the development of a BTC cancer screening methodology and the data on their usability as a potential predictive biomarker for BTCs of response to systemic therapy.<br /> (© 2024 Martina Rebersek et al., published by Sciendo.)

Details

Language :
English
ISSN :
1581-3207
Volume :
58
Issue :
2
Database :
MEDLINE
Journal :
Radiology and oncology
Publication Type :
Academic Journal
Accession number :
38553250
Full Text :
https://doi.org/10.2478/raon-2024-0026